Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders.

Neurological research and practice·2026
Same author

Glatiramer acetate stimulates phagocytosis and intracellular killing of <i>Escherichia coli</i> by macrophages and microglial cells.

Frontiers in immunology·2026
Same author

Microglia-associated progression of multiple sclerosis: target identification and therapeutic engagement in human in vitro models.

Experimental & molecular medicine·2026
Same author

Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.

Therapeutic advances in neurological disorders·2025
Same journal

Correction: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. <i>Pharmaceuticals</i> 2026, <i>19</i>, 522.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Correction: Zhao et al. Multifunctional Gel Films of Marine Polysaccharides Cross-Linked with Poly-Metal Ions for Wound Healing. <i>Pharmaceuticals</i> 2022, <i>15</i>, 750.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Icariin Attenuates Renal Injury in Streptozotocin-Induced Diabetic Rats with and Without Adenine-Induced Chronic Kidney Disease.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

AI-Assisted Identification of a Putative Allosteric Ligand Targeting the CDK4/Cyclin D1 Protein-Protein Interface.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Development and Study of Hydrophilic Ointment Compositions with a Dextrin/Polyvinyl Alcohol/Iodine Complex (D/PVA/I).

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K

Towards Treating Multiple Sclerosis Progression.

Darius Häusler1,2, Martin S Weber1,2,3

  • 1Institute of Neuropathology, University Medical Centre, 37075 Goettingen, Germany.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) involves central nervous system inflammation and demyelination. Current treatments manage relapses but are less effective for progressive MS (PMS), highlighting the need for new therapeutic strategies.

Keywords:
clinical trialscompartmentalized inflammationmultiple sclerosisneuroprotectionneurorepairprogressionregenerationremyelinationtherapytreatment

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.0K

Related Experiment Videos

Last Updated: Jun 6, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.0K

Area of Science:

  • Neuroimmunology
  • Neurology
  • Pathophysiology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).
  • MS pathology involves distinct mechanisms during relapsing-remitting and progressive phases, including CNS-intrinsic processes.
  • Existing disease-modifying therapies primarily target peripheral immunity and are more effective against relapses than progression.

Purpose of the Study:

  • To review the pathological mechanisms underlying MS progression.
  • To summarize current therapeutic strategies for progressive MS (PMS).
  • To discuss emerging treatment targets for novel PMS therapies.

Main Methods:

  • Review of pathological mechanisms in MS progression.
  • Summary of approved and investigational therapeutics for PMS.
  • Discussion of potential future treatment targets.

Main Results:

  • MS progression involves CNS-intrinsic pathophysiology, including slowly expanding lesions and brain atrophy, which initiates early in the disease.
  • Current MS treatments effectively reduce relapses but show limited efficacy in halting disease progression.
  • Several novel treatment options for PMS are under investigation, targeting different pathological pathways.

Conclusions:

  • Understanding the CNS-intrinsic mechanisms of MS progression is crucial for developing effective treatments.
  • There is a significant unmet need for therapies that can halt or reverse progressive MS.
  • Future research should focus on novel therapeutic targets addressing the specific pathologies of PMS.